Clinical trials: Chemotherapy Induced Neutropenia
Chemotherapy-induced Neutropenia
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) of single subcutaneous (SC) injection of GW003 in healthy subjects.
- Trial name
- NCT02643901
- Testing
- GW003
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Solid Tumors, Malignant Hemopathy
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.
- Conditions
- Solid Tumors, Malignant Hemopathy, Chemotherapy-induced Febrile Neutropenia (FN)
- Trial name
- NCT01574235
- Testing
- Nivestim®
- Where
- 87 sites in France
- Volunteers
- 2,114 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Colorectal Cancer, Chemotherapy-induced Neutropenia
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
The primary objective of this study is to assess the efficacy of monosialotetrahexosylganglioside (GM1) for preventing oxaliplatin induced neurotoxicity in colorectal cancer patients who received oxaliplatin-based adjuvant…
- Trial name
- NCT02251977
- Testing
- GM1, mFOLFOX6 or XELOX
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Yuhong Li
Hematologic Neoplasms, Neutropenia
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.
- Conditions
- Hematologic Neoplasms, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT05672420
- Testing
- umbilical cord derived mesenchymal stem cells
- Where
- 3 sites in China
- Volunteers
- 181 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chemotherapy-induced Neutropenia
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
The purpose of the present trial is to evaluate the safety, tolerability and pharmacokinetics(PK)/pharmacodynamics(PD) of single subcutaneous injection of GW003 in breast cancer patients.
- Trial name
- NCT02725606
- Testing
- Pegylated Recombinant Human G-CSF, GW003
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia
Efficacy and Safety Study With MYL-1401H and Neulasta
This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.
- Trial name
- NCT02467868
- Testing
- MYL-1401H, Neulasta
- Where
- 36 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 193 people
- Sponsor
- Mylan Inc.
Chemotherapy-induced Febrile Neutropenia
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
- Trial name
- NCT02178475
- Where
- 74 sites in Austria, Belgium and 7 more
- Volunteers
- 943 people
- Sponsor
- Amgen
Neutropenia
Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients
To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.
- Trial name
- NCT00364468
- Testing
- pegfilgrastim
- Where
- 6 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer, Cancer-related Problem/Condition
Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.
Introduction: The number of diagnosed cancers is systematically increasing every year. Cancer patients need to undergo regular blood tests to monitor safety and eligibility for treatment.
- Conditions
- Cancer, Cancer-related Problem/Condition, Chemotherapy, Chemotherapy-induced Neutropenia
- Trial name
- AMBeR eBlood (NCT06809101)
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Pomeranian Medical University Szczecin
Extensive-stage Small-cell Lung Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
- Trial name
- NCT05874401
- Testing
- Trilaciclib, Topotecan
- Where
- Spain
- Volunteers
- 302 people
- Sponsor
- Pharmacosmos A/S
Neoplasms, Chemotherapy-induced Neutropenia
Study to Evaluate the Usability of PointCheck
This a study about the usability of PointCheck a novel non-invasive technology for monitoring chemotherapy-induced neutropenia. The study will include patients with cancer visiting the outpatient hematology clinic for their…
- Trial name
- NCT04448314
- Testing
- PointCheck
- Where
- 3 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Leuko Labs, Inc.
Leukemia, Neutropenia
Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00002719
- Testing
- filgrastim, amsacrine, carmustine
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pediatric Cancer, Febrile Neutropenia
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied.
- Conditions
- Pediatric Cancer, Febrile Neutropenia, Chemotherapy-induced Neutropenia, Oncology
- Trial name
- NCT04134429
- Testing
- Everion
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of…
- Trial name
- ADVANCE (NCT02643420)
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 406 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Epithelial Ovarian Cancer
Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.
- Trial name
- NCT01680575
- Where
- South Korea
- Volunteers
- 750 people
- Sponsor
- Asan Medical Center
Chemotherapy-induced Neutropenia
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Evaluation of the efficacy and safety of recombinant human serum albumin / granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced neutropenia
- Trial name
- NCT03251768
- Testing
- rHSA-GCSF 2.4mg, GCSF
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Fever, Sweats, and Hot Flashes, Neutropenia
Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
RATIONALE: Antibiotics may decrease the side effects of neutropenia and fever caused by chemotherapy. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and…
- Conditions
- Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003739
- Testing
- filgrastim
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 67 people
- Sponsor
- Children's Oncology Group
Chemotherapy-induced Neutropenia
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and…
- Trial name
- NCT04227990
- Testing
- Plinabulin, Pegfilgrastim, Docetaxel, doxorubicin, and cyclophosphamide (TAC)
- Where
- 11 sites in China, Ukraine
- Volunteers
- 115 people
- Sponsor
- BeyondSpring Pharmaceuticals Inc.
Breast Cancer, Chemotherapy-Induced Neutropenia
Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSF
This prospective, multicenter, non-randomized controlled study aims to evaluate bone pain associated with prophylactic use of long-acting granulocyte colony-stimulating factors (G-CSFs) in patients with breast cancer receiving…
- Conditions
- Breast Cancer, Chemotherapy-Induced Neutropenia, Febrile Neutropenia, Bone Pain
- Trial name
- Bone Pain (NCT07806084)
- Volunteers
- 132 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University